|
Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). |
|
|
Honoraria - AstraZeneca; Clovis Oncology; Nucana |
Consulting or Advisory Role - AstraZeneca (Inst); Clovis Oncology (Inst); Nucana (Inst) |
Research Funding - Aprea AB (Inst); AstraZeneca (Inst); Novartis (Inst); Nucana |
Patents, Royalties, Other Intellectual Property - One patent issued and four pending for a gene expression signature to predict cancer sensitivity to anti-angiogenic therapy. (Inst) |
|
|
Honoraria - AstraZeneca; Pfizer |
Consulting or Advisory Role - AstraZeneca; Pfizer |
|
|
Consulting or Advisory Role - AstraZeneca; Genentech; Immunogen; Merck KGaA; Tesaro |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Clovis Oncology; Roche |
Consulting or Advisory Role - AstraZeneca; Clovis Oncology |
Speakers' Bureau - Prime Oncology |
Research Funding - Clovis Oncology; Roche/Genentech |
Expert Testimony - AstraZeneca |
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; Roche |
Other Relationship - Clovis Oncology |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
|
|
Honoraria - AstraZeneca; Pfizer |
Consulting or Advisory Role - AstraZeneca/MedImmune; Clovis Oncology; Pfizer; Roche |
Research Funding - AstraZeneca (Inst) |